Risedronic acid

Drug Profile

Risedronic acid

Alternative Names: Acrel; Actonel; Actonel Combi; Actonel plus Calcium; Actonel with Calcium; Atelvia; Benet; NE-58095; NE-58095NF; Optinate; Optinate Septimum; Ribastamin; Risedronate; Risedronate sodium; Sodium risedronate hydrate; WC3051

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Procter & Gamble
  • Developer Ajinomoto; Allergan; Procter & Gamble; Sanofi; Takeda
  • Class Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteitis deformans
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Corticosteroid-induced osteoporosis; Male osteoporosis; Osteitis deformans; Osteoporosis; Postmenopausal osteoporosis
  • Discontinued Osteogenesis imperfecta

Most Recent Events

  • 10 May 2017 Development of risedronic acid discontinued at phase II/III for Osteoporosis in Japan (PO,new tablet formulation) during 2016 (Takeda FY2016 results, May 2017)
  • 15 Mar 2016 Biomarkers information updated
  • 23 Mar 2015 Discontinued - Phase-III for Osteogenesis imperfecta (In children) in USA, Australia, Belgium, Chile, Czech Republic, Finland, Germany, Hungary, Italy, Poland, South Africa, Spain and the UK (PO, tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top